A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris
Status:
Completed
Trial end date:
2020-01-10
Target enrollment:
Participant gender:
Summary
Open-label cohort study in adult patients with newly diagnosed or relapsing pemphigus
vulgaris, with intra-patient dose-adjustment based on clinical response and BTK occupancy,
and with conventional immunosuppressive "rescue treatment", if indicated. The duration of
therapy in Part A will be 12 weeks, followed by 12 weeks of follow up. The extension phase,
Part B includes 24 weeks of therapy, followed by 4 weeks of follow-up.
Phase:
Phase 2
Details
Lead Sponsor:
Principia Biopharma, a Sanofi Company Principia Biopharma, Inc.